Abstract
Charged particle therapy (proton beam therapy and carbon ion therapy) is a form of radiotherapy which has the unique characteristic of superior depth dose distribution, and has been used for the treatment of hepatocellular carcinoma (HCC) in a limited number of patients, especially in Japan. We undertook a systematic review to define the clinical utility of charged particle therapy for patients with HCC. We searched the MEDLINE database from 1983 to June 2016 to identify clinical studies on charged particle therapy for HCC. Primary outcomes of interest were local control, overall survival, and late radiation morbidities. A total of 13 cohorts from 11 papers were selected from an initial dataset of 78 papers. They included a randomized controlled trial comparing proton beam therapy with transarterial chemoembolization, 9 phase I or II trials and 2 retrospective studies. The reported actuarial local control rates ranged from 71.4–95% at 3 years, and the overall survival rates ranged from 25–42.3% at 5 years. Late severe radiation morbidities were uncommon, and a total of 18 patients with grade ≥3 late adverse events were reported among the 787 patients included in this analysis. Charged particle therapy for HCC was associated with good local control with limited probability of severe morbidities. The cost-effectiveness and the distinctive clinical advantages of charged particle therapies should be clarified in order to become a socially accepted treatment modality for HCC.
Similar content being viewed by others
References
Petrick JL, Braunlin M, Laversanne M et al (2016) International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 139(7):1534–1545. doi:10.1002/ijc.30211
Zhang Y, Ren JS, Shi JF et al (2015) International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer 15:94. doi:10.1186/s12885-015-1113-4
Natinal Comprehensive Cancer Network (2017) Hepatobiliary cancers. In: NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed Mar. 2017
Japan Society of Hepatology (2013) Evidence-based clinical practice guidelines for hepatocellular carcinoma, 3rd edn. Kanehara Shuppan, Tokyo
Japan Society of Hepatology (in press) Clinical practice guidelines for hepatocellular carcinoma, 4th edn. Kanehara Shuppan, Tokyo
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535
Bush DA, Kayali Z, Grove R et al (2011) The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 117(13):3053–3059. doi:10.1002/cncr.25809
Bush DA, Smith JC, Slater JD et al (2016) Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 95(1):477–482. doi:10.1016/j.ijrobp.2016.02.027
Fukumitsu N, Sugahara S, Nakayama H et al (2009) A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 74(3):831–836. doi:10.1016/j.ijrobp.2008.10.073
Hong TS, DeLaney TF, Mamon HJ et al (2014) A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol 4(5):316–322. doi:10.1016/j.prro.2013.10.002
Hong TS, Wo JY, Yeap BY et al (2016) Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 34(5):460–468. doi:10.1200/JCO.2015.64.2710
Kato H, Tsujii H, Miyamoto T et al (2004) Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59(5):1468–1476. doi:10.1016/j.ijrobp.2004.01.032
Kawashima M, Furuse J, Nishio T et al (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23(9):1839–1846. doi:10.1200/JCO.2005.00.620
Kim TH, Park JW, Kim YJ et al (2015) Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat 47(1):34–45. doi:10.4143/crt.2013.218
Komatsu S, Fukumoto T, Demizu Y et al (2011) Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 117(21):4890–4904. doi:10.1002/cncr.26134
Lee SU, Park JW, Kim TH et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190(9):806–814. doi:10.1007/s00066-014-0604-6
Tsujii H, Mizoe J, Kamada T et al (2007) Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 48(Suppl A):A1–A13
ICRU (2007) Prescribing, recording, and reporting proton-beam therapy
Chiba T, Tokuuye K, Matsuzaki Y et al (2005) Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 11(10):3799–3805. doi:10.1158/1078-0432.CCR-04-1350
Matsuzaki Y, Osuga T, Chiba T et al (1995) New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma. Intern Med 34(4):302–304
Matsuzaki Y, Osuga T, Saito Y et al (1994) A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 106(4):1032–1041
Tanaka N, Matsuzaki Y, Chuganji Y et al (1992) Proton irradiation for hepatocellular carcinoma. Lancet 340(8831):1358
Particle Therapy Co-operative Group (2017) Particle therapy facilities in operation. https://www.ptcog.ch/index.php/facilities-in-operation. Accessed Mar 2017
Bush DA, Hillebrand DJ, Slater JM et al (2004) High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127(5 Suppl 1):S189–S193
Slater JM, Miller DW, Archambeau JO (1988) Development of a hospital-based proton beam treatment center. Int J Radiat Oncol Biol Phys 14(4):761–775
Coutrakon G, Hubbard J, Johanning J et al (1994) A performance study of the Loma Linda proton medical accelerator. Med Phys 21(11):1691–1701. doi:10.1118/1.597270
Nakayama H, Sugahara S, Tokita M et al (2009) Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 115(23):5499–5506. doi:10.1002/cncr.24619
Pan CC, Kavanagh BD, Dawson LA et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S94–S100. doi:10.1016/j.ijrobp.2009.06.092
Kawashima M, Kohno R, Nakachi K et al (2011) Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 79(5):1479–1486. doi:10.1016/j.ijrobp.2009.12.048
Yoon HI, Koom WS, Lee IJ et al (2012) The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int 32(7):1165–1171. doi:10.1111/j.1478-3231.2012.02784.x
Mizumoto M, Oshiro Y, Okumura T et al (2014) Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy. Radiother Oncol 113(1):54–59. doi:10.1016/j.radonc.2014.08.015
Sugahara S, Nakayama H, Fukuda K et al (2009) Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185(12):782–788. doi:10.1007/s00066-009-2020-x
Hata M, Tokuuye K, Sugahara S et al (2005) Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 104(4):794–801. doi:10.1002/cncr.21237
Kim DY, Park JW, Kim TH et al (2017) Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol 122(1):122–129. doi:10.1016/j.radonc.2016.12.014
Mizumoto M, Okumura T, Hashimoto T et al (2011) Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81(4):1039–1045. doi:10.1016/j.ijrobp.2010.07.015
Hata M, Tokuuye K, Sugahara S et al (2007) Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69(3):805–812. doi:10.1016/j.ijrobp.2007.04.016
Mizumoto M, Tokuuye K, Sugahara S et al (2008) Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 71(2):462–467. doi:10.1016/j.ijrobp.2007.09.056
Sugahara S, Oshiro Y, Nakayama H et al (2010) Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 76(2):460–466. doi:10.1016/j.ijrobp.2009.02.030
Hashimoto T, Tokuuye K, Fukumitsu N et al (2006) Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 65(1):196–202. doi:10.1016/j.ijrobp.2005.11.043
Koike S, Ando K, Uzawa A et al (2002) Significance of fractionated irradiation for the biological therapeutic gain of carbon ions. Radiat Prot Dosimetry 99(1–4):405–408
Ando K, Koike S, Uzawa A et al (2005) Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res 46(1):51–57
Imada H, Kato H, Yasuda S et al (2010) Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol 96(2):231–235. doi:10.1016/j.radonc.2010.05.019
Kamada T, Tsujii H, Blakely EA et al (2015) Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 16(2):e93–e100. doi:10.1016/S1470-2045(14)70412-7
Combs SE, Habermehl D, Ganten T et al (2011) Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer 11:67. doi:10.1186/1471-2407-11-67
Habermehl D, Debus J, Ganten T et al (2013) Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma—feasibility and clinical response. Radiat Oncol 8:59. doi:10.1186/1748-717X-8-59
Pedroni E, Bacher R, Blattmann H et al (1995) The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys 22(1):37–53. doi:10.1118/1.597522
Gillin MT, Sahoo N, Bues M et al (2010) Commissioning of the discrete spot scanning proton beam delivery system at the University of Texas M.D. Anderson Cancer Center, Proton Therapy Center, Houston. Med Phys 37(1):154–163. doi:10.1118/1.3259742
Shimizu S, Miyamoto N, Matsuura T et al (2014) A proton beam therapy system dedicated to spot-scanning increases accuracy with moving tumors by real-time imaging and gating and reduces equipment size. PLoS One 9(4):e94971. doi:10.1371/journal.pone.0094971
Schneider U, Agosteo S, Pedroni E et al (2002) Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 53(1):244–251
Furukawa T, Inaniwa T, Sato S et al (2010) Performance of the NIRS fast scanning system for heavy-ion radiotherapy. Med Phys 37(11):5672–5682. doi:10.1118/1.3501313
United States National Institute of Health (2009) Transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma. In: ClinicalTrails.gov. https://clinicaltrials.gov/ct2/show/NCT00857805. Accessed Mar 2017
United States National Institute of Health (2013) Comparison between radiofrequency ablation and hypofractionated proton beam radiation for recurrent/residual HCC. In: ClinicalTrails.gov. https://clinicaltrials.gov/ct2/show/NCT01963429. Accessed Mar. 2017
American Society for Radiation Oncology (2014) Proton beam therapy model policy issued by ASTRO. https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2014/Proton-Beam-Therapy-Model-Policy-issued-by-ASTRO/. Accessed Mar 2017
Kokudo N, Hasegawa K, Akahane M et al (2015) Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 45(2):123–127. doi:10.1111/hepr.12464
Korean Liver Cancer Study Group, National Cancer Center Korea (2015) 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 9(3):267–317. doi:10.5009/gnl14460
Korean Liver Cancer Study Group, National Cancer Center Korea (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16(3):465–522. doi:10.3348/kjr.2015.16.3.465
Ryder SD, British Society of Gastroenterology (2003) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52(Suppl 3):iii1–iii8
Ferenci P, Fried M, Labrecque D et al (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44(4):239–245. doi:10.1097/MCG.0b013e3181d46ef2
Omata M, Lesmana LA, Tateishi R et al (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4(2):439–474. doi:10.1007/s12072-010-9165-7
Abdo AA, Hassanain M, AlJumah A et al (2012) Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 32(2):174–199
European Association for Study of Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48(5):599–641. doi:10.1016/j.ejca.2011.12.021
Verslype C, Rosmorduc O, Rougier P et al (2012) Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):41–48. doi:10.1093/annonc/mds225
Carrillo FJ, Mattos AA, Vianey AF et al (2015) Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol 52(Suppl 1):2–14. doi:10.1590/S0004-28032015000500001
Nakayama H, Sugahara S, Fukuda K et al (2011) Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 80(4):992–995. doi:10.1016/j.ijrobp.2010.03.015
Mizumoto M, Tokuuye K, Sugahara S et al (2007) Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: report of three cases. Jpn J Clin Oncol 37(6):459–462. doi:10.1093/jjco/hym038
Hata M, Tokuuye K, Sugahara S et al (2006) Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 182(12):713–720. doi:10.1007/s00066-006-1564-2
Hata M, Tokuuye K, Sugahara S et al (2006) Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 107(3):591–598. doi:10.1002/cncr.22039
Mayahara H, Oda Y, Kawaguchi A et al (2005) A case of hepatocellular carcinoma initially treated by carbon ions, followed by protons for marginal recurrence with portal thrombus. Radiat Med 23(7):513–519
Acknowledgements
The authors would like to thank the following foundation and individuals for their assistance in developing this report. The general incorporated foundation of the Japan Society of Hepatology (Tokyo, Japan) developed and implemented the search strategy and conducted a literature search. Dr. Atsuya Takeda (Ofuna Chuo Hospital) and Dr. Ken Harada (Tokai University) helped with screening and retrieval of the literature review. This study was supported in part by JSPS KAKENHI [Grant numbers 16K10410 (Grant recipient: HI), 15H04901 (Grant recipient: HS), 16K10383 (Grant recipient: TO)].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Igaki, H., Mizumoto, M., Okumura, T. et al. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int J Clin Oncol 23, 423–433 (2018). https://doi.org/10.1007/s10147-017-1190-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-017-1190-2